Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Soleno Therapeutics in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K. Kluska expects that the company ...

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO – Get Free Report) have received a consensus recommendation of “Buy” from the seven research firms that are covering the company, MarketBeat.com ...

Two Nebraska researchers have launched a startup company aimed at bringing to market an innovative method for delivering therapeutics, gene editing tools, plasmids and more to targeted locations in ...

Aileron Therapeutics pulled a hard pivot in 2023, merging with Lung Therapeutics to gain a new pipeline and investor base. | ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

REDWOOD CITY, CA—Soleno Therapeutics Inc. (NASDAQ:SLNO), a $1.98 billion market cap biopharmaceutical company, recently disclosed a series of stock sales by Kristen Yen, the company's Senior Vice ...

Patricia Hirano, Senior Vice President of Regulatory Affairs at Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold shares of the company. According to a filing with the Securities and Exchange ...

Anish Bhatnagar, the Chief Executive Officer of Soleno Therapeutics Inc. (NASDAQ:SLNO), recently sold a significant portion of the company's stock. According to an SEC filing, Bhatnagar sold a total ...

About Leap Therapeutics Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized ...